Rheumnow Podcast

PsA Treatment: is Earlier Better?

Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.

JAK Inhibitors for New Indications

Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.

Transition from Psoriasis to PsA: Can we Prevent It?

Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.

EULAR 2024 Daily Recap - Days 1 & 2

Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis

Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Voclosporin and Steroids in Lupus Nephritis

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

 

3 Big Lupus Themes from EULAR 2024

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. 

Does B Cell Depletion Matter?

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.